MedTrace Logo

Shortened LSD Intervention for Major Depressive Disorder

NCT07503002 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Conditions

Interventions

DRUG

LSD

Participants will be administered LSD followed 45-minutes later by risperidone.

DRUG

Risperidone

Participants will be administered LSD followed 45-minutes later by risperidone.

Sponsors & Collaborators

Principal Investigators

  • Sandeep Nayak, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-07-01
Completion
2027-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07503002 on ClinicalTrials.gov